BACHELET, T.; VISENTIN, Jonathan; DAVIS, P.; TATON, B.; GUIDICELLI, G.; KAMINSKI, Hannah; MERVILLE, Pierre; COUZI, Lionel

doi:10.1111/ctr.14171

Métadonnées

Licence d’utilisation du document

VISENTIN, Jonathan
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

DAVIS, P.

Langue

Article de revue

Ce document a été publié dans

Clinical Transplantation. 2021-02, vol. 35, n° 2, p. e14171

Résumé en anglais

Background: Rituximab has been proposed as induction therapy in kidney transplant recipients (KTRs) with preformed donor-specific antibodies (DSA) or a positive flow cross-match. We here evaluated whether adding rituximab was associated with a higher incidence of post-transplant malignancies (PTM) due to greater immunosuppression. Patients and Methods: Forty-eight HLA-sensitized KTRs received induction therapy with anti-thymocyte globulin (ATG) and rituximab because of preformed DSA or a positive flow cross-match (RTX group). They were compared with a control group of 154 patients receiving ATG alone. Results: Thirty-nine of 202 (19.3%) patients developed PTM; the rate was similar in the RTX and no-RTX groups (14.6% vs. 20.8%, respectively, P=.3). The distributions of the types of cancer were similar between the two groups, with the majority being non-melanoma skin cancer (NMSC, n=24). The risk factors for PTM were male gender, age, history of cancer, and azathioprine. Conclusion: Our data do not indicate a higher rate of post-transplantation de novo malignancies after kidney transplantation in high-immunological risk patients who received induction therapy based on ATG and rituximab.< Réduire

Mots clés en anglais

Alloantibodies

B-cell therapy

Malignancy

Rituximab

Métadonnées

Partager cette publication !

Licence d’utilisation du document

The incidence of post-transplant malignancies in kidney transplant recipients treated with Rituximab

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche